PHA Final Exam Fall 2006

Similar documents
PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA First Exam Fall 2003

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA 5128 Spring 2000 Final Exam

PHA First Exam Fall 2013

PHA First Exam. Fall 2004

PHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Final Exam Fall 2001

PHA Spring First Exam. 8 Aminoglycosides (5 points)

PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.

General Principles of Pharmacology and Toxicology

PHA 5128 Spring 2009 First Exam (Version B)

PHA5128 Dose Optimization II Case Study I Spring 2013

PHARMACOKINETICS SMALL GROUP I:

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

Thus, we can group the entire loading dose together as though it was given as a single dose, all administered when the first dose was given.

Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment

Multiple IV Bolus Dose Administration

1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?

TDM. Measurement techniques used to determine cyclosporine level include:

BIOPHARMACEUTICS and CLINICAL PHARMACY

. Although there is a little

PHAR 7633 Chapter 20 Non Compartmental Analysis

Name: UFID: PHA Exam 2. Spring 2013

General Principles of Pharmacology and Toxicology

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

BASIC PHARMACOKINETICS

PHAR 7632 Chapter 16

Basic Concepts of TDM

PHARMACOKINETICS SMALL GROUP II:

PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007

Pharmacokinetic Calculations

One-Compartment Open Model: Intravenous Bolus Administration:

TDM of Aminoglycoside Antibiotics

Pharmacokinetics One- compartment Open Model Lec:2

Understand the physiological determinants of extent and rate of absorption

Nonlinear Pharmacokinetics

ADME Review. Dr. Joe Ritter Associate Professor of Pharmacology

Case Study 2 Answers Spring 2006

CLINICAL PHARMACOKINETICS INDEPENDENT LEARNING MODULE

Biopharmaceutics Lecture-11 & 12. Pharmacokinetics of oral absorption

Pharmacokinetics Applied to the Treatment of Asthma

Lippincott Questions Pharmacology

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

PHA 5128 Case Study 4 (Answers) Total Cp = Unbound Cp/fu.

Rational Dose Prediction. Pharmacology. φαρμακον. What does this mean? pharmakon. Medicine Poison Magic Spell

LD = (Vd x Cp)/F (Vd x Cp)/F MD = (Css x CL x T)/F DR = (Css x (Vm-DR))/Km Css = (F x D)/(CL x T) (Km x DR)/(Vm DR)

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

The general Concepts of Pharmacokinetics

Tala Saleh. Abdul Aziz ALShamali. Abdul Aziz ALShamali

TDM Lecture 7 5 th Stage. TDM of Digoxin. Uses: Digoxin is usually used in heart failure associated and atrial fibrillation.

Pharmacokinetics in Drug Development. Edward P. Acosta, PharmD Professor & Director Division of Clinical Pharmacology Director, CCC PK/PD Core

PHA Case Studies V (Answers)

Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook with Computer Simulations

NIH Public Access Author Manuscript Transplant Proc. Author manuscript; available in PMC 2010 September 22.

PHA5128 Dose Optimization II Case Study 3 Spring 2013

Renal Function. 1. Glomerular filtration 2. Active tubular secretion 3. Passive tubular reabsorption 4. Excretion

Pharmacokinetics of strong opioids. Susan Addie Specialist palliative care pharmacist

C OBJECTIVES. Basic Pharmacokinetics LESSON. After completing Lesson 2, you should be able to:

Principles of Pharmacokinetics

Tamer Barakat. Abdul Aziz ALShamali. Abdul Aziz ALShamali

Determination of bioavailability

Pharmacokinetic parameters: Halflife

Carbamazepine has a clearance of L/h/kg for monotherapy. For immediate release carbamazepine, the oral bioavailbility is 0.8

Introduction to Pharmacokinetics (PK) Anson K. Abraham, Ph.D. Associate Principal Scientist, PPDM- QP2 Merck & Co. Inc., West Point, PA 5- June- 2017

Pharmacokinetics of Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Basic Concepts in Pharmacokinetics. Leon Aarons Manchester Pharmacy School University of Manchester

Section 5.2: Pharmacokinetic properties

Pharmacokinetics I. Dr. M.Mothilal Assistant professor

INTRODUCTION TO PHARMACOKINETICS

Based on the information in the official labeling, please answer the following:

Pharmacokinetics Overview

Principal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA

Pharmacokinetics of drug infusions

prophylaxis for endocarditis in patients at high risk prophylaxis for major surgical procedures

PHARMACOKINETICS OF DRUG ABSORPTION

SHC Vancomycin Dosing Guide

Chapter 12 DRUG THERAPY 2001 Dennis A. Noe

Renal Impairment From Dettli to Guideline: What can we learn?

Muhammad Fawad Rasool Feras Khalil Stephanie Läer

Metformin: Mechanistic Absorption Modeling and IVIVC Development

Pharmacokinetic Modeling & Simulation in Discovery and non-clinical Development

The importance of clearance

Introduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

Biomath M263 Clinical Pharmacology

Aminoglycosides. Uses: Treatment of serious gram-negative systemic infections and some grampositive

WHY... 8/21/2013 LEARNING OUTCOMES PHARMACOKINETICS I. A Absorption. D Distribution DEFINITION ADME AND THERAPEUIC ACTION

Pharmacology/Therapeutics I Block I Handouts

A primer on pharmacology

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The ADME properties of most drugs strongly depends on the ability of the drug to pass through membranes via simple diffusion.

Drug elimination and Hepatic clearance Chapter 6

Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University

UNIVERSITY OF THE WEST INDIES, ST AUGUSTINE

Transcription:

PHA 5127 Final Exam Fall 2006 On my honor, I have neither given nor received unauthorized aid in doing this assignment. Name Please transfer the answers onto the bubble sheet. The question number refers to the number on the bubble sheet. Please fill in all the information necessary to identify yourself. The proctors will also collect your exams. Good LUCK. Total Questions 31 (5 points each) Total Points 155 +2 bonus= 157 1

Question 1: Select the correct statement(s). The plasma drug concentration versus time curve for a two-compartment model is (5 points) 1 biexponential 2 monoexponential 3 based on zero order pharmacokinetic processes 4 based on first order pharmacokinetic processes The correct statement(s) are (is): A: 1 B: 2 and 3 C: 1 and 4 D: 1 and 3 E: 2 and 3 Question 2: We have defined several volumes of distribution when talking about a 2- compartment model (5 points). The correct statement(s) are (is) The volume of distribution in a 2 compartment model: 1 relates the amount of drug in the body to the plasma concentration. 2 is decreasing with time after drug administration, as the amount of the drug in the body is decreasing. 3 during the beta-phase does not depend clearance. 4 is changing because it takes time for the drug to enter and leave the peripheral compartment. 5 is changing from the time of administration up to the elimination phase, as the relative amount of drug in the peripheral compartment, (when compared to the amount in the central compartment), is changing. A: (1, 2, 3, 4, 5) B: (1, 2, 4, 5) C: (1, 2, 5) D: (1, 4, 5) E: (1, 4) 2

Question 3-6: The following applies to questions 3-6: A 60-kg patient is begun on a continuous intravenous infusion of theophylline at 36 mg/hr (based on theophylline, not aminophylline). Forty-eight hours after beginning of the infusion, the plasma concentration is 12 mg/l. Question 3: If we assume that this concentration is at steady state, what is the theophylline volume of distribution? (5 points) A: 0.25 L/kg B: Not enough information to provide answer. C: 30 L D: 18 L/day E: None of the above A 60-kg patient is begun on a continuous intravenous infusion of theophylline at 36 mg/hr (based on theophylline, not aminophylline). Question 4: If we assume that the volume of distribution is is 30 L, and the clearance is 3.3 L/hr what is the half-life? Please perform calculations on paper, we will check. (5 points) A: 1.7 hr B: 6.3 hr C: 13.3 hr D: 22.1 hr E: 45.3 hr 3

A 60-kg patient is begun on a continuous intravenous infusion of theophylline at 36 mg/hr (based on theophylline, not aminophylline). Question 5: : If the volume of distribution is estimated to be 30 L, and the clearance is 3.3 L/hr, what would the plasma concentration be 3 days after beginning of the infusion? Remember: the infusion rate is 36 mg/hr (based on theophylline, not aminophylline) Please perform calculations, we might check. (5 points) A: 3.2 µg/ml B: 4.8 µg/ml C: 8.1 µg/ml D: 10.9 µg/ml E: None of the above. A 60-kg patient is begun on a continuous intravenous infusion of theophylline at 36 mg/hr (based on theophylline, not aminophylline). Question 6: Assume that the volume of distribution is 30 L, and the clearance is 3.3 L/hr. If the infusion is continued for 4 days and then discontinued, what would the plasma concentration be 12 hours after the stop of the infusion? Please perform calculations, we might check. (5 points) A 1.2 mg/l B: 2.9 mg/l C: 7.6 mg/l D: 8.1 mg/l E: None of the above 4

Question 7: Assume that the volume of distribution is estimated to be 30 L, and the clearance is 3.3 L/hr. What infusion rate would likely result in a steady state concentration of 24 mg/l. Please perform calculations, we will check. (5 points) Round appropriately. A: 10 mg/h B: 30 mg/h C: 40 mg/h D: 80 mg/h E: None of the above. The following pertains to Questions 8-9 A 60 kg patient is started on 80 mg of gentamycin given every 6 hr as 1-hr infusion. Question 8: This patient is assumed to have an average volume of distribution (value of the population mean) of 0.25 L/kg and a normal half life of 3 hr, what would be the peak plasma concentration after the first infusion (one hour after the stop of the infusion). Please provide calculations. (5 points). Round appropriately. A: 3.8 mg/l B: 4.8 mg/l C: 5.1 mg/l D: 15.4 mg/l E: None of the above 5

A 60 kg patient is started on 80 mg of gentamycin given every 6 hr as 1-hr infusion. Question 9: Based on above information, what is the fluctuation that you can expect? Please provide calculations. Round appropriately.(5 points) A: 1 B: 2 C: 3 D: 4 E: None of the above 6

Questions 10-14 (5 points each) The following questions 10-14are related to parts of equations that are shown in the equation blocks A, B, C, D, E (see bottom of page). Question 10: What form of administration is captured by the equation whose parts (blocks) are listed in A, B, D, E (C is not included for this question)? (5 points) A: single iv bolus injection B: multiple oral absorption C: multiple bolus injections D: multiple short term infusions Identify the block that best fits the following statements. (SELECT FROM BLOCKS A- E shown below) Question 11: A factor suitable to quantify how much a single short term infusion is away from the steady state level that would be observed if a patient receives the drug with the same k o for an extended period of time. A Question 12: This block is necessary to allow calculation of the Trough concentration at steady state from C max values, when given either as multiple short term infusions or multiple iv bolus injections E Question 13: C max after the first dose when given as a short term infusion C 7

Question 14: Degree of accumulation (at steady state) observed when drug is given either as multiple bolus injections or short term infusions. D A. (1 e k e T ) B. k o /CL k0 k C. ( r T 1 e ) CL 1 D. τ 1 e k e E. e -k e t 8

Question 15: The oral bioavailability of a lipophilic drug that is only eliminated through renal filtration (5 points) 1 will be high if it shows sufficient solubility 2 will depend on liver blood flow 3 will depend on plasma protein binding 4 might be low if it shows affinity to transporters in the GI tract that pump drug into the GI fluid. 5 will be affected by the GFR Select the correct statement(s): A: 1, 2, 3 B: 4, 5 C: 2, 3 D: 3, 4 E 1, 4 9

Question 16-23: Patient 1 and 2received a drug as an iv bolus injection. Pharmacokinetic and physiological characteristics, such as dose, fraction of the drug unbound in plasma and tissue, intrinsic clearance, liver blood flow, and volume of plasma and volume of the tissue water in these patient are shown below. TABLE 1: INPUT PARAMETERS Patient 1 Patient 2 D [mg] 40 40 fu 1 1 fut 0.3 0.3 CLi [L/h] 30,000 30,000 Q [L/h] 90 45 Vp [L] 3 3 VTW [L] 38 38 The next table shows the resulting pharmacokinetic parameters in Patient 1. Please circle in the free column of the Table 2 for each parameter whether the parameter (Peak concentration, Ke, V, Cl, t 1/2, E, F, AUC) will be about the same (B), will be larger (A), or will be smaller (C) than those estimates observed in Patient 1. Mark on the bubble sheet the appropriate A, B, C Table 2: OUTPUT PARAMETERS Question: Patient 1 Patient 2 16 (5 points) Peak[μg/ml] 0.3 Larger (A), about the same (B), Smaller (C) 17 (5 points) Ke [1/h] 0.69 Larger (A), about the same (B), Smaller (C) 18 (5 points) V [L] 130 Larger (A), about the same (B), Smaller (C) 19 (5 points) CL [L/h] 89.7 Larger (A), about the same (B), Smaller (C) 20 (5 points) t1/2 [h] 1.0 Larger (A), about the same (B), Smaller (C) 21 (5 points) E 0.99 Larger (A), about the same (B), Smaller (C) 22 (5 points) F [%] for tablet 0.3 Larger (A), about the same (B), Smaller (C) 23 (5 points) AUC [μg/ml*h] 0.446 Larger (A), about the same (B), Smaller (C) 10

Question 24: Imagine a low extraction drug that is given orally. Two patients differ only in the degree of plasma protein binding for this drug. Patient 1 shows a higher plasma protein binding than Patient 2. When given the same dose, the AUC of free drug for Patient 1 will be larger (a), smaller (b), about the same (c) as the AUC of free drug in Patient 2 or (d) not enough information provided. (5 points) A: smaller B: larger C: about the same D: not enough information provided. Question 25: Imagine a high extraction drug that is given orally. Two patients differ only in the degree of plasma protein binding for this drug. Patient 1 shows a higher plasma protein binding than Patient 2. When given the same dose, the AUC of free drug for patient 1 will be larger (a), smaller (b), about the same (c) as the AUC of free drug in Patient 2, or (d) not enough information provided. A: smaller B: larger C: about the same D: not enough information provided. 11

Question 26: Which of the following factors might significantly affect the renal clearance of an ionized acidic drug (pka= 1) that has a molecular weight of 200 Dalton? (5 pts) 1. plasma protein binding 2. activity of cationic transporters in the tubuli. 3. urine flow 4. ph of urine 5. liver blood flow All answers were accepted A: 1, 2, 3, B: 1, 3, C: 1, 3, 4, 5, D: 1, 3, 5, E: 1, 2 12

Mark whether the following statements are true (A) or false (B). Name: Question 27 (5 points) T (A) F (B) Loading doses are mainly given for drugs with large volume of distribution and/or low clearance Question 28 (5 points) T (A) F (B) Assume that the oral bioavailability of a drug is 100%. If the oral absorption of this drug is very fast, plasma time profiles after oral absorption and iv bolus injection will be very similar shortly after administration of the dose. Question 29 (5 points) T (A) F (B) Assume a drug with an oral bioavailability of 100% and a halflife after iv administration of 2 hours. When this drug is given as a sustained release formulation one can assume that the fluctuation will be the same as when the same dose is given as multiple iv bolus injections using the same tau. Question 30 (5 points) T (A) F (B) 200 mg given every 12 hours will result in the same fluctuation than 400 mg given once a day. Question 31 (5 points) T (A) F (B) 200 mg given every 12 hours will result in the same AUC than 400 mg given once a day. 13